WATERTOWN, Mass.–(BUSINESS WIRE)–Treeline Biosciences (or Treeline) today announced the initiation of Phase 1 trials for two internally discovered programs, TLN-121 and TLN-372, and a third in-licensed program, TLN-254. TLN-121, a BCL6 degrader, and TLN-254, an EZH2…
According to filings with the U.S. Securities and Exchange Commission, Treeline Biosciences is raising up to $421,779,808.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Joshua Bilenker played a…
Stamford, CT – According to filings with the U.S. Securities and Exchange Commission, Treeline Biosciences is raising $261,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Joshua Bilenker played a…